Centre Hospitalier Universitaire De Besancon
Clinical trials sponsored by Centre Hospitalier Universitaire De Besancon, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Light-Based therapy may tame kidney transplant rejection Results expected Oct 2026 (estimated)
- Can a simple ultrasound score prevent fluid overload in the ICU? Results expected Oct 2026 (estimated)
- New wrist scanner could slash radiation and speed up 3D imaging Results expected Oct 2026 (estimated)
- Blood test may spot pancreatic cancer early, study hopes Results expected Dec 2026 (estimated)
- Heart scans could uncover silent damage in liver patients awaiting transplant Results expected Mar 2027 (estimated)
-
Can a simpler chemo schedule tame colorectal cancer with fewer side effects?
Disease control CompletedThis trial tests whether giving the chemotherapy drugs raltitrexed and oxaliplatin every two weeks is as effective and less toxic than the standard every-three-week schedule in people with metastatic colorectal cancer who have not had prior chemotherapy. Some participants also re…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can standard cancer treatment wake up the immune system? a study investigates.
Knowledge-focused CompletedThis study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boos…
Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New blood test may predict immunotherapy success in cancer patients
Knowledge-focused CompletedThis study looked at whether measuring specific immune responses (anti-telomerase T cells) in the blood can help predict how well cancer patients will respond to immunotherapy drugs like anti-PD1/PDL1. Researchers enrolled 295 adults with advanced or metastatic cancer who were ab…
Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Cancer patients speak out: what they really want from pharmacy visits
Knowledge-focused CompletedThis study asked 167 people with cancer (and their caregivers) what they value most during pharmacy consultations for oral cancer drugs. Using a survey method, researchers identified key preferences to help hospitals design better support services. The goal was to improve patient…
Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC